Sprint Bioscience
Pipeline

Development portfolio

Target   
FBDD Discovery  
Preclinical  
Clinical Development  
Solid tumors
Licensed to Day One Biopharmaceuticals
Melanoma
Leukemia
Solid tumors
Solid tumors
MASH
Undisclosed
Portfolio

Developing small molecule drug programs focusing on oncology, diseases that go under the term cancer

We work with a broad portfolio and develop several parallel programs in the preclinical phase in a short time until we have a potential drug candidate ready to be licensed to the pharmaceutical market. Our programs are mainly in three areas of biology, all of which are important for cancer cell growth and survival.

These three focus areas overlap, providing valuable synergies between the programs. This makes us efficient and helps to build a unique expertise that both facilitates the selection of target proteins and makes Sprint Bioscience an attractive license partner.

Tumor metabolism

Cancer cells, due to their rapid growth, depend on a constant supply of energy and building blocks in a way that differs from the needs of healthy cells. This creates a vulnerability in cancer cells that is exploited in the programs Sprint Bioscience is developing in this area. By blocking the metabolic pathways specific to the tumor, they can be starved and tumor growth blocked.

The tumor microenvironment

A tumor is usually a mixture of cancer cells and other cell types normally found in the body. These normal cells have often been reprogrammed by the cancer cells to contribute to the growth of the tumour. One of the characteristics of a tumour is a poor blood supply, which creates an environment that is very different from the rest of the body. This environment is called the tumor microenvironment. The different cell types in the tumor need to adapt to this environment, and by developing drugs that block this adaptation, tumor growth can be stopped.

Immuno-oncology

The field of immuno-oncology is about developing treatments to help the body's own immune system fight cancer. For a tumor to form in the body, cancer cells need to find ways to escape the immune system. The programs we are developing in this area focus on blocking these mechanisms so that the tumor can be identified and fought by the immune system.

Pipeline